Quantcast

PanGenex (PGXC) Expands Internationally to Puerto Rico at the Expo 2008 Coopharma

October 9, 2008

PanGenex Corporation (Pink Sheets:PGXC) is pleased to announce that the Company will be represented by its International Product Liaison, Dr. Jimmy Diaz, at the Expo 2008 Coopharma held at the Intercontinental San Juan Resort and Casino today thru Sunday October 12th. Coopharma represents over 300 innovative pharmacies throughout Puerto Rico and this opportunity facilitates the introduction of PanGenex products, such as the all-natural cholesterol solution LIPIDEME(TM), into the Puerto Rican marketplace.

“As a doctor, I am very pleased to see the excitement in the market for proven natural alternatives to toxic medication. This week I will meet with 364 pharmacy owners in Puerto Rico that want to offer a natural alternative to medications. The international market has great respect for American Products. I am very proud to represent a company that prides itself to be at the cutting edge of this market. The PanGenex products are research-based, pharmaceutical grade, reasonably priced and natural. In the next few weeks I will be targeting Mexico, with its 100 million people and the European Market with 370 million people,” explained Dr. Diaz.

“We are excited to have Dr. Diaz’s involvement with Coopharma. This is a progressive opportunity for our company as the demand for all-natural solutions for health concerns such as high cholesterol and wellness grows globally,” states Jeff Roman, President and CEO of PanGenex. “We expect Dr. Diaz to solidify multiple orders through this event and his prior involvement with these pharmacies and practitioners.”

Learn More About Coopharma at:

http://www.coopharma.coop/

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

Disclaimer:

Cautionary Statement about Forward-Looking Statements

This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,”"anticipates,”"intends,”"plans,”"believes,”"seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.




comments powered by Disqus